The potential for PARP inhibitors like Veliparib in melanoma treatment, especially when combined with other therapies, could offer a promising avenue for overcoming resistance mechanisms, but specific clinical trials focused on melanoma will be essential to fully understand its efficacy. The gene discussed is PARP1; the disease is melanoma.